Cebix Raises $16M From Investors

Bruce V. Bigelow9/1/10

San Diego-based Cebix, which is developing a replacement therapy based on human proinsulin C-peptide as a supplemental treatment for complications from type 1 diabetes, has raised $16 million over the past 14 months, according to a form filed with regulators Monday. The form amends a regulatory filing that Cebix submitted in June, 2009, which disclosed it had raised almost $2.3 million. The two-year-old startup has made no announcements about the funding or investors, but representatives of Sofinnova Ventures, InterWest Partners, Thomas McNerny & Partners, and Creative Peptides of Stockholm, Sweden, are on its board.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788